Imported Genotype 2B Rubella Virus Caused the 2012 Outbreak in Anqing City, China

PLoS One. 2015 Sep 24;10(9):e0139173. doi: 10.1371/journal.pone.0139173. eCollection 2015.

Abstract

A rubella outbreak occurred in Anqing city of Anhui province, China, from February to July of 2012, and a total of 241 clinically diagnosed or lab-confirmed patients were reported. The highest number of rubella cases during this outbreak was recorded in teenagers between 10 and 19 years of age who had not previously received the rubella vaccine. Genotyping results indicated that the genotype 2B rubella virus (RV) was responsible for the outbreak. However, a phylogenetic analysis showed that the genotype 2B RVs isolated in Anqing City were not related to 2B RVs found in other cities of Anhui province and in other provinces of China, thus providing evidence for importation. After importation, the transmission of Anqing RVs was interrupted owing to an effective immunization campaign against rubella, suggesting the timeliness and effectiveness of contingency vaccination. Strengthening rubella surveillance, including the integration of epidemiologic information and laboratory data, is a vital strategy for rubella control and elimination. In addition, except for routine immunization, targeted supplementary immunization activities aimed at susceptible groups according to sero-epidemiological surveillance data also play a key role in stopping the continuous transmission of rubella viruses and in preventing further congenital rubella syndrome cases.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Age Distribution
  • China / epidemiology
  • Cities / statistics & numerical data*
  • Disease Outbreaks / statistics & numerical data*
  • Genotype
  • Geography
  • Humans
  • Phylogeny
  • Rubella / epidemiology*
  • Rubella / virology*
  • Rubella virus / genetics*
  • Rubella virus / isolation & purification

Grants and funding

This work was supported by the National Natural Science Foundation of China (project no. 81101244), Key Technologies R&D Program of National Ministry of Science (2013ZX10004-202, 2012ZX10004201-003, and 2012ZX10004215), National Science and Technology Major Project for Creation of Major New Drugs (2013ZX09304101), and WHO Measles Regional Reference Laboratory funding (WPCHN1002802). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.